ACCURAY INC

Accuray Incorporated received approval from Nasdaq to transfer its common stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective August 6, 2026. The company's common stock will continue to trade under the symbol "ARAY". Accuray has been granted an additional 180 days, until February 1, 2027, to demonstrate compliance with The Nasdaq Capital Market's $1.00 bid price requirement.

Accuray Incorporated announced a comprehensive plan to strengthen its financial position, securing $55.0 million through the issuance of Series A Convertible Preferred Stock. This includes a $15.0 million cash investment and the conversion of $40.0 million in existing debt held by TCW Asset Management Company LLC. The plan also involves the cancellation of warrants for approximately 27.6 million common shares, a future reverse stock split, and new strategic partnerships with Samsung HME America and RaySearch Laboratories, alongside an expanded collaboration with Tata Consultancy Services.

Accuray Incorporated announced the full repayment of its 3.75% Convertible Senior Notes due 2026 on June 1, 2026. The company repaid the remaining outstanding aggregate principal amount of $18,000,000, along with $337,500 in accrued and unpaid interest. In conjunction with this repayment, the related Indenture was satisfied and discharged, releasing Accuray from its remaining obligations under the agreement.

Accuray reported a significant increase in net loss for the three and nine months ended March 31, 2026, alongside a decrease in total net revenue. The company also received a notice from Nasdaq regarding non-compliance with the minimum bid price rule, giving it until August 3, 2026, to regain compliance. Macroeconomic factors, supply chain issues, and reduced capital deployment for radiotherapy equipment continue to impact financial performance.

Accuray reported its fiscal 2026 third-quarter financial results, including a net loss of $11.8 million on total net revenue of $104.8 million, a 7% decrease year-over-year. The company withdrew its financial guidance for fiscal year 2026, citing geopolitical uncertainty in the Middle East impacting product shipments and service revenue. Despite the challenges, Accuray noted significant progress on its transformation plan, achieving approximately $10 million in cost and margin improvements, ahead of expectations.

Accuray Incorporated announced that Leonel Peralta, Senior Vice President and Chief Operations Officer, departed from the company effective April 26, 2026. The company clarified that Mr. Peralta's resignation was not a result of any disagreement with the company or its Board of Directors, nor any matter related to the company's operations, policies, or practices.

Accuray amended its consulting agreement with Dedication Capital, an affiliate of board member Steven F. Mayer. The amendment reduces cash compensation by 50% for certain periods and accelerates the vesting of a significant portion of restricted stock awards, resulting in at least $362,500 in cash savings for the company.

Accuray Incorporated announced the appointment of Paul Miele as the company's Senior Vice President and Chief Commercial Officer, effective April 6, 2026. This management change could impact the company's commercial strategy and sales performance, making it relevant for investors to monitor.